Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients

Rationale: Despite the success of several standards of care treatment options in metastatic castration-resistant prostate cancer (mCRPC), a significant number of patients attain therapeutic resistance and eventually develop disease progression. Managing these patients are currently challenging. Henc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Madhav Prasad, Ballal, Sanjana, Sahoo, Ranjit Kumar, Tripathi, Madhavi, Seth, Amlesh, Bal, Chandrasekhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415797/
https://www.ncbi.nlm.nih.gov/pubmed/32802197
http://dx.doi.org/10.7150/thno.48107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415797/
https://www.ncbi.nlm.nih.gov/pubmed/32802197
http://dx.doi.org/10.7150/thno.48107

Ejemplares similares